Figure 2.

Effect of sorafenib and CPPD on ERK1/2 activation and NOXA expression in HB cells. Western blot analysis of pERK1/2 after treatment with sorafenib (3 μℳ) with or without pre-incubation of CDDP (HUH6: 0.5; 2 μg ml⁻¹ (A) and HepT1: 1; 4 μg ml⁻¹ (B)). (C) Expression of NOXA in HB cells using qRT-PCR after treatment with sorafenib (3 μℳ) and CDDP (2 μg ml⁻¹).